Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial of Transcatheter Arterial Chemoembolization With Drug Eluting Beads (DEB-TACE) Versus Sorafenib in the Treatment of Unresectable, Locally Advanced Hepatocellular Carcinoma

NCT02460991 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT02460991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02460991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial of Transcatheter Arterial Chemoembolization With Drug Eluting Beads (DEB-TACE) Versus Sorafenib in the Treatment of Unresectable, Locally Advanced Hepatocellular Carcinoma
Lead sponsor
Boston Scientific Corporation
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2015
Completion date
June 5, 2017
Enrollment
2 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, hepatoma, liver cell carcinoma